Literature DB >> 28922738

Mixed symptoms in major depressive and bipolar disorders: A systematic review.

Gustavo H Vázquez1, María Lolich2, Casimiro Cabrera3, Ruzica Jokic3, Dusan Kolar3, Leonardo Tondo4, Ross J Baldessarini5.   

Abstract

BACKGROUND: The DSM-5 mixed features specifier for mood disorders encourages renewed interest in mixed states and led us to pool research findings regarding prevalence of mixed features in episodes of major depressive (MDD) and bipolar disorders (BD).
METHODS: We systematically searched to July 2017 for reports on mixed symptoms in depressive episodes of MDD and in depression and mania or hypomania in types I and II BD. For primary mood-states and diagnostic groups we compared rates of the presence of mixed symptoms: as defined by DSM-5 (≥3 features opposite to the dominant mood-polarity but not overlapping those of the primary disorder) or as having any ≥3 features of opposite polarity.
RESULTS: We identified 17 reports, from 13 world regions involving 19,198 participants meeting standard diagnostic criteria for an index major depressive or [hypo]manic episode. Prevalence of cases with ≥3 features of opposite polarity averaged 27.8% [CI: 27.2-28.5] overall, and differed significantly between BD and MDD disorders, ranking: BD-depressed (35.2% [33.8-36.5]) = BD-[hypo]manic (35.1% [32.9-37.3]) > MDD-depressed (23.8% [23.0-24.5]). LIMITATIONS: Available findings were limited to mood disorders with mixed features by particular criteria, with few comparisons to other criteria or to their prognostic or therapeutic implications.
CONCLUSIONS: Prevalence of ≥3 features of opposite polarity ranked: depressive = [hypo]manic episodes of BD > depression in MDD.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Diagnosis; Hypomania; Major depression; Mania; Mixed features

Mesh:

Substances:

Year:  2017        PMID: 28922738     DOI: 10.1016/j.jad.2017.09.006

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

Review 1.  Treatment of Mixed Features in Bipolar Disorder: an Updated View.

Authors:  Trisha Chakrabarty; Kamyar Keramatian; Lakshmi N Yatham
Journal:  Curr Psychiatry Rep       Date:  2020-02-06       Impact factor: 5.285

2.  Exploration of mood spectrum symptoms during a major depressive episode: The impact of contrapolarity-Results from a transdiagnostic cluster analysis on an Italian sample of unipolar and bipolar patients.

Authors:  Ludovico Mineo; Alessandro Rodolico; Giorgio Alfredo Spedicato; Andrea Aguglia; Simone Bolognesi; Carmen Concerto; Alessandro Cuomo; Arianna Goracci; Giuseppe Maina; Andrea Fagiolini; Mario Amore; Eugenio Aguglia
Journal:  Eur Psychiatry       Date:  2022-05-31       Impact factor: 7.156

3.  Efficacy, Safety, and Tolerability of Theta-Burst Stimulation in Mixed Depression: Design, Rationale, and Objectives of a Randomized, Double-Blinded, Sham-Controlled Trial.

Authors:  Diego Freitas Tavares; Carla Garcia Rodrigues Dos Santos; Leandro Da Costa Lane Valiengo; Izio Klein; Lucas Borrione; Pamela Marques Forte; Andre R Brunoni; Ricardo Alberto Moreno
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

4.  Psychometric Properties of the Chinese Version of the Bipolar Depression Rating Scale for Bipolar Disorder.

Authors:  Jing-Xu Chen; Lu Yin; Hai-Ting Xu; Suo-Yuan Zhang; Wen-Qian Huang; Hong-Juan Li; Bin-Bin Li; Ke-Bing Yang; Qian Li; Michael Berk; Yun-Ai Su
Journal:  Neuropsychiatr Dis Treat       Date:  2021-03-12       Impact factor: 2.570

5.  The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study.

Authors:  Changsu Han; Sheng-Min Wang; Won-Myong Bahk; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-11-20       Impact factor: 2.582

6.  Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.

Authors:  Gustavo H Vázquez; Anees Bahji; Juan Undurraga; Leonardo Tondo; Ross J Baldessarini
Journal:  J Psychopharmacol       Date:  2021-07-09       Impact factor: 4.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.